25 results
424B5
NBSE
NeuBase Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
8:42am
with the regulations applicable to the activities being conducted. Although we plan to oversee the contract manufacturers, we cannot control
424B5
NBSE
NeuBase Therapeutics Inc
29 Dec 22
Prospectus supplement for primary offering
5:03pm
plan to oversee the contract manufacturers, we cannot control the manufacturing process of, and will be completely dependent on, our contract
424B5
NBSE
NeuBase Therapeutics Inc
27 Aug 21
Prospectus supplement for primary offering
5:21pm
conducted. Although we plan to oversee the contract manufacturers, we cannot control the manufacturing process of, and will be completely dependent on, our
8-K
EX-99.1
a1i1qaj
12 Aug 21
NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights
4:18pm
8-K
EX-99.1
qewsdq
20 May 21
NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer
9:00am
424B5
3lptrha3
23 Apr 21
Prospectus supplement for primary offering
4:05pm
424B5
r7ua96t4ypy9t521
21 Apr 21
Prospectus supplement for primary offering
4:03pm
424B3
9ypk knrs2qjuylo8sb
6 Jun 19
Prospectus supplement
5:15pm
S-4/A
cteblyhthob1l
16 Apr 19
Registration of securities issued in business combination transactions (amended)
5:29pm